Two patients (3.4%) had an adverse reaction to dalbavancin; one patient experienced phlebitis following their first dalbavancin dose then tolerated their second, another developed drug-induced neutropaenia to a trough of 0.8 × 109/L, which was successfully treated with granulocyte colony-stimulating factor. This evidence concerns the gene CSF3 and phlebitis.